10,339 Shares in Glaukos Corporation $GKOS Purchased by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 10,339 Glaukos shares during the second quarter, valued at approximately $1.45 million. Institutional investors collectively own 99.04% of the company.
• Glaukos reported strong quarterly growth, with revenue rising 49.6% year over year to $185.61 million and an adjusted loss of $0.14 per share, beating analysts’ expectations. The company remains unprofitable, with analysts forecasting a full-year loss.
• Analyst sentiment remains broadly positive: 12 analysts rate GKOS a Buy, with a consensus “Moderate Buy” rating and a $178.08 price target. However, insiders sold more than $19.6 million of shares over the past 90 days.

B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,339 shares of the medical instruments supplier's stock, valued at approximately $1,445,000.

Other institutional investors have also recently made changes to their positions in the company. Stephens Inc. AR bought a new position in shares of Glaukos during the 1st quarter valued at $363,000. DNB Asset Management AS grew its holdings in shares of Glaukos by 11.9% in the fourth quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier's stock worth $9,295,000 after acquiring an additional 8,770 shares during the period. Quantinno Capital Management LP increased its position in Glaukos by 964.0% during the first quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier's stock valued at $3,320,000 after acquiring an additional 27,938 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier's stock valued at $152,476,000 after acquiring an additional 913,458 shares during the last quarter. Finally, Landscape Capital Management L.L.C. lifted its holdings in Glaukos by 125.3% in the fourth quarter. Landscape Capital Management L.L.C. now owns 23,017 shares of the medical instruments supplier's stock valued at $2,599,000 after acquiring an additional 12,799 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $185.66 on Monday. The firm has a market cap of $10.95 billion, a price-to-earnings ratio of -57.13 and a beta of 0.78. The firm has a fifty day moving average price of $157.38 and a 200 day moving average price of $131.72. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm's revenue for the quarter was up 49.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.24) earnings per share. As a group, sell-side analysts expect that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 60,000 shares of Glaukos stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares in the company, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 20,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 113,025 shares of company stock worth $19,600,006 in the last ninety days. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GKOS. Stifel Nicolaus upped their price target on shares of Glaukos from $175.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Piper Sandler restated an "overweight" rating and set a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. William Blair reaffirmed an "outperform" rating on shares of Glaukos in a report on Tuesday, May 26th. JPMorgan Chase & Co. increased their price target on shares of Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th. Finally, UBS Group assumed coverage on shares of Glaukos in a research note on Tuesday, July 28th. They set a "neutral" rating and a $150.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $178.08.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source